Abstract
Inflammatory bowel diseases (IBD) are considered barrier diseases. After misleading initial results, the pathogenic importance of a disturbed mucosa is now widely accepted, largely because a certain percentage of first-degree relatives of patients with IBD do have permeability alterations, as assessed by oral markers. In the presence of a normal appearing gut mucosa, functional alterations of the highly dynamic inter-enterocyte tight junctions have to be considered to be responsible for the observed alterations. Indeed, various alterations of the transmembrane and intracytoplasmic proteins have been reported in IBD. An important therapeutic goal is to maintain disease remission by preservation of the correct organization of these complexes. Of the potential therapeutic approaches, the various anti-TNF agents are the best-studied agents, but other treatments may tighten the gut through as yet unknown mechanisms.
Keywords: Barrier function, claudins, IBD, intestinal permeability, MLCK, TNF-, occludin, tight junctions.
Current Drug Targets
Title:Sealing the Broken Barrier in IBD: Intestinal Permeability, Epithelial Cells and Junctions
Volume: 14 Issue: 12
Author(s): Walter Fries, Alessandra Belvedere and Stefania Vetrano
Affiliation:
Keywords: Barrier function, claudins, IBD, intestinal permeability, MLCK, TNF-, occludin, tight junctions.
Abstract: Inflammatory bowel diseases (IBD) are considered barrier diseases. After misleading initial results, the pathogenic importance of a disturbed mucosa is now widely accepted, largely because a certain percentage of first-degree relatives of patients with IBD do have permeability alterations, as assessed by oral markers. In the presence of a normal appearing gut mucosa, functional alterations of the highly dynamic inter-enterocyte tight junctions have to be considered to be responsible for the observed alterations. Indeed, various alterations of the transmembrane and intracytoplasmic proteins have been reported in IBD. An important therapeutic goal is to maintain disease remission by preservation of the correct organization of these complexes. Of the potential therapeutic approaches, the various anti-TNF agents are the best-studied agents, but other treatments may tighten the gut through as yet unknown mechanisms.
Export Options
About this article
Cite this article as:
Fries Walter, Belvedere Alessandra and Vetrano Stefania, Sealing the Broken Barrier in IBD: Intestinal Permeability, Epithelial Cells and Junctions, Current Drug Targets 2013; 14 (12) . https://dx.doi.org/10.2174/1389450111314120011
DOI https://dx.doi.org/10.2174/1389450111314120011 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel Drugs and the Response to Hypoxia: HIF Stabilizers and Prolyl Hydroxylase
Recent Patents on Cardiovascular Drug Discovery Targeting Cytotoxic Conjugates of Somatostatin, Luteinizing Hormone- Releasing Hormone and Bombesin to Cancers Expressing Their Receptors: A “Smarter” Chemotherapy
Current Pharmaceutical Design Changes in Market Share of Biologic and Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs for Treatment of Rheumatoid Arthritis: Results from the Ontario Best-Practice Research Initiative Database
Current Rheumatology Reviews AMPK - Activated Protein Kinase and its Role in Energy Metabolism of the Heart
Current Cardiology Reviews Diagnostic Value of the Early Heart-to-Mediastinum Count Ratio in Cardiac 123I-mIBG Imaging for Parkinson's Disease
Current Radiopharmaceuticals Management of Patients with Heart Failure: Focus on New Pharmaceutical and Device Options
Current Medicinal Chemistry Beta-Blockers as First Line Treatment of Hypertension: A Proponents View
Current Hypertension Reviews The Role of Cytokines in Sleep Regulation
Current Pharmaceutical Design Treatment of Obesity: Should We Target the Individual or Society?
Current Pharmaceutical Design Infection-Associated Biomarkers of Inflammation in Atherosclerosis
Current Pharmaceutical Design Editorial (Thematic Issue: Switching to Biological Agents in Autoimmune and Autoinflammatory Disorders: Current Targets and Therapy)
Current Medicinal Chemistry Acute Management in Very Old Patients: Is Thrombolysis Safe?
Cardiovascular & Hematological Disorders-Drug Targets Angiotensin (1-7) and other Angiotensin Peptides
Current Pharmaceutical Design PEDF as an Emerging Therapeutic Candidate for Osteosarcoma
Current Cancer Drug Targets Editorial (Thematic Issue: Recent Advances in Management of Myocarditis)
Current Pharmaceutical Design From the Oxygen to the Organ Protection: Erythropoietin as Protagonist in Internal Medicine
Cardiovascular & Hematological Agents in Medicinal Chemistry Drug-Induced QTc Interval Prolongation: A Multicenter Study to Detect Drugs and Clinical Factors Involved in Every Day Practice
Current Drug Safety Glycogen Synthase Kinase-β3 in Ischemic Neuronal Death
Current Neurovascular Research Facilitated/Pharmaco-invasive Approaches in STEMI
Current Cardiology Reviews Altered Expression of microRNAs in Serum Extracellular Vesicles in Rats with Severe Burns during Shock Stage
Current Molecular Medicine